VR Eye-Tracking Screening and Cognitive Training for Alzheimer's

• Тест на 3D-көру қабілеті
• Көрудің контрасттық сезімталдығы
• Видео немесе жазбаша консультация

• Трансфер қосылмаған

VR Eye‑Tracking for Alzheimer’s Disease:
How It Works
Alzheimer’s disease (AD) is the most common cause of dementia, yet it often goes undiagnosed until significant damage has occurred. Virtual reality (VR) combined with high‑precision eye‑tracking offers a new way to detect early cognitive decline and deliver targeted cognitive training. This approach does not cure AD, but it provides objective, scalable tools for early screening and non‑pharmacological intervention.
The Equipment
A typical VR eye‑tracking system consists of three components:
A VR headset​ that immerses the user in realistic, interactive environments (e.g., virtual supermarket shopping, catching fireflies, or navigating a street).
High‑speed infrared eye‑tracking cameras​ embedded in the headset, sampling gaze position at up to 1000 Hz. They record fixation points, saccades (rapid eye jumps), smooth pursuit, micro‑saccades, and pupil diameter changes.
An AI analysis engine​ that processes tens of thousands of eye‑movement data points per session and maps them onto established cognitive scales (e.g., MoCA, MMSE).
The entire assessment typically takes only 5 minutes, is non‑invasive, requires no verbal response, and collects over 20,000 eye‑movement parameters covering attention, memory, executive function, calculation, abstraction, and recall.
Detection Principle: Why Eyes Reveal Cognition
Eye movements are controlled by brain regions that are among the first affected by Alzheimer’s pathology. Four well‑documented abnormalities are consistently observed in people with mild cognitive impairment (MCI) or AD:
Impaired basic oculomotor control​ – difficulty maintaining steady fixation, increased intrusive saccades, and disrupted smooth pursuit. Studies report that basic eye‑movement tasks alone can differentiate AD from healthy aging with ~95% accuracy.
Elevated antisaccade error rates​ – when asked to look away from a suddenly appearing target instead of toward it, AD patients fail 50–80% of trials, compared to about 20% in healthy controls. This inhibitory deficit correlates strongly with disease severity.
Abnormal visual search patterns​ – longer reaction times, more fixations on irrelevant objects, and reduced attention to salient cues during scene exploration.
Reduced novelty preference in recognition memory​ – in a visual paired‑comparison task, MCI/AD patients spend less time looking at novel images than familiar ones, a pattern that can predict conversion from MCI to AD within one year.
Machine‑learning models integrating these eye‑movement features with demographic and clinical data achieve AUC values around 0.84 for MCI detection and sensitivity/specificity above 0.80 for distinguishing AD from normal cognition. However, current studies mostly lack gold‑standard biomarkers (e.g., amyloid PET or CSF p‑tau), so VR eye‑tracking is best used as a screening and monitoring tool, not a standalone diagnostic.
Therapeutic Principle: Cognitive Rehabilitation via Neuroplasticity
On the treatment side, VR eye‑tracking systems serve as a platform for personalized cognitive rehabilitation. After an initial assessment, the AI generates a training regimen composed of gamified tasks that adapt in real time to the user’s performance. These tasks challenge specific cognitive domains:
Episodic memory (remembering items in a virtual room)
Executive function (planning a route, inhibiting distractions)
Attention (tracking moving targets, filtering noise)
The underlying mechanism is activity‑dependent neuroplasticity: repeated, challenging cognitive engagement stimulates synaptic remodeling, promotes release of neurotrophic factors, and helps maintain functional connectivity in networks vulnerable to AD. Some programs also combine cognitive exercises with physical movement (e.g., virtual table tennis) to enhance brain‑body coordination.
Clinical evidence shows that regular, long‑term VR cognitive training can improve attention, memory, and daily living skills in people with MCI or mild AD, and may slow the rate of cognitive decline. It is particularly valuable because the immersive, game‑like format increases patient engagement and adherence compared to traditional paper‑and‑pencil drills.
Important Caveats
VR eye‑tracking cannot cure Alzheimer’s. Its value lies in early detection and non‑drug intervention.
Diagnosis of AD still requires biomarker confirmation (CSF, PET, MRI).
The technology is already approved as a Class II medical device in some countries (e.g., China) for cognitive assessment and rehabilitation.
In summary, VR eye‑tracking turns the eyes into a window for cognitive health. It provides a fast, objective, and scalable method for detecting early signs of Alzheimer’s and delivers personalized brain training that may help preserve function for longer.

• Жеке дәрігер-координатор
• Сапарды ұйымдастыру — біздің серіктестерден төмендетілген бағамен билеттер мен қонақ үйлерді брондау
• Клиникаға бару барысында науқас мүдделерін қорғау